Clinical Trials

EOM613 has early clinical stage safety and efficacy data in various disease states. Below are examples of early exploratory stage safety and efficacy data in patients with AIDS, cancer cachexia, and rheumatoid arthritis.

EOM613

Clinical Development Initiated and Planned 
Recruitment is currently underway for R1: RESCUE, a Phase 1/2a open-label clinical study in Brazil evaluating EOM613 in severe COVID-19 patients with “cytokine storm” immune responses

Phase 2a multicenter trial planned evaluating EOM613 in cancer cachexia in the US

Further clinical development of EOM613 includes initiating exploratory trials for rheumatoid arthritis

Early Clinical Stage Safety and Efficacy Data for EOM613*

Disease/ Disorder, SourceStudy Type and Design# of PatientsEfficacy FindingsSafety/Tolerability Findings
HIV/AIDS1 (Levett et al., 2002)

Study Type and Design

  • Phase 1/2, randomized, double-blind, placebo-controlled trial
  • Conducted in Barbados

# of Patients

  • 43 (21 EOM613, 22 placebo)

Efficacy Findings

  • CD4 lymphocyte counts increased vs baseline more in EOM613 group vs placebo group (p=0.013)
  • 4 EOM613 patients (but no placebo patients) had significant viral load declines
  • Body weight increased vs baseline in EOM613 group (p=0.003) whereas placebo group had a mean weight loss (p=0.003 for group difference)

Safety/Tolerability Findings

  • EOM613 injections generally well tolerated
  • Some patients reported transient mild pain at injection site
  • No toxic effects of EOM613 reported by patients or observed by physicians
Rheumatoid Arthritis (RA)2 (EOM data on file)

Study Type and Design

  • Phase 2, open-label trial
  • Patients given EOM613 1 mL twice daily for 15 days, then once daily for 75 days
  • Conducted in Argentina

# of Patients

  • 27 patients who met American College of Rheumatology criteria for mid to moderately severe RA

Efficacy Findings

  • After 3 months of EOM613 therapy, all patients:
    • Responded with amelioration of symptoms
    • Had a significant decrease in joint pain
    • Had increased mobility of the joints
    • Showed objective signs of decreased inflammation of affected joints
    • Considered efficacy as excellent

Safety/Tolerability Findings

  • No major side effects observed or reported
  • All patients considered tolerability as excellent
Cancer Cachexia3
(Chasen et al., 2013)

Study Type and Design

  • Phase 2, open-label trial
  • Conducted in Canada

of Patients

  • 29 enrolled patients with advanced cancer and cachexia

Efficacy Findings

  • Stabilization of weight, lean body mass and body fat
  • Appetite increased (p=0.001) and total PG-SGA scores improved significantly (p=0.025)
  • Enhanced quality of life and Karnofsky Performance Status

Safety/Tolerability Findings

  • EOM613 was well tolerated with minimal side effects

*In these and other past reports, EOM613 has had other names, including Product R, OHR118, AVR118, and OHR/AVR118.

EOM147 is an investigational, broad-spectrum aminosterol with a unique intracellular mechanism for the treatment of retinal diseases. EOM147 affects multiple angiogenic growth factors such as VEGF, PdGF, and bFGF. This mechanism of action is uniquely differentiated from other retinal therapies that are only anti-VEGF and administered as an intraocular injection. The novel formulation, administered as an eye drop, represents a potential breakthrough that does not require intraocular injection.

EOM147

Upcoming Clinical Trial of EOM147

EOM Pharmaceuticals is planning Phase 2 ophthalmic trials to be conducted for macular edema in patients with diabetic retinopathy and in wet age-related macular degeneration (wet-AMD) with the novel formulation of EOM147 to be conducted at sites in Mexico and India. The eye drop will be used as monotherapy, without adjunctive intraocular injections being administered.

An additional trial is planned for the use of EOM147 eye drop in branch and central retinal vein occlusions (BRVO and CRVO) in the United States, based on the promising results obtained in a previous investigator-initiated trial in 20 patients.

Completed Clinical Trials of EOM147*

Disease/ Disorder, SourceStudy Type and Design# of PatientsEfficacy FindingsSafety/Tolerability Findings
Macular edema due to retinal vein Occlusion1 (Wroblewski and Hu, 2016)
  • Phase 1, proof-of-concept study
  • Single-center, open-label randomized trial
  • Patients treated with topical squalamine (OHR102) and intravetral ranibizumab for 10 weeks, followed by randomization to continue or discontinue squalamine
20 treatment-naïve patientsAt week 38, best-corrected visual acuity improved mean best-corrected visual acuity significantly more in patients who continued squalamine vs stoppedSqualamine and ranbizumab were well tolerated

*In this and other past reports, EOM147 has had other names, including OHR-102

Published Articles

Randomized, placebo-controlled trial of product R, a peptide-nucleic acid immunomodulator, in the treatment of adults infected with HIV. Levett PN, Hirschman SZ, Roach TC, Broome H, Alexander RJ, Fraser HS. HIV Clin Trials. 2002 Jul-Aug;3(4):272-8. doi: 10.1310/N34A-653T-ABF5-8Q1R. PMID: 12187500.

Anti-cachectic effects of a novel peptide nucleic acid: Preliminary results of a phase I/II clinical trial. D’Olimpio JT, Hirschman SZ, Shtemer Z, Didiego M. DOI: 10.1200/jco.2004.22.90140.8087 (presentation abstract). Journal of Clinical Oncology. July 15, 2004; 22, no. 14_suppl 8087-8087.

A Phase II study of OHR/AVR118 in anorexia-cachexia. Chasen M, Bhargava R, Hirschman SZ, Taraporewala IB. Poster presentation at: the 7th Cachexia conference, Kobe/Osaka, Japan, December 9-11, 2013.

Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia/cachexia. Chasen M, Hirschman SZ, Bhargava R. J Am Med Dir Assoc. 2011 Jan;12(1):62-7. doi: 10.1016/j.jamda.2010.02.012. Epub 2010 May 15. PMID: 21194662.

Activation of human monocytes/macrophages by OHR/AVR118 promotes both pro– and anti-inflammatory phenotypes. Hirschman SZ. Adv Biosci Biotch. 2014; 5:161-8.

Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study. Wroblewski JJ, Hu AY. Ophthalmic Surg Lasers Imaging Retina. 2016 Oct 1;47(10):914-923. doi: 10.3928/23258160-20161004-04. PMID: 27759857.

IL-8 and MCP-1 secretion is enhanced by the peptide-nucleic acid immunomodulator, Product R, in U937 cells and primary human monocytes. D A Lazzarino, M de Diego, S Z Hirschman, K Y Zhang, S Shaikh, E Musi, L Liaw, R J Alexander. Cytokine. 2001 May 21;14(4):234-9. PMID: 11448124  DOI: 10.1006/cyto.2001.0867.

CXCR4 and CCR5 expression by H9 T-cells is downregulated by a peptide-nucleic acid immunomodulator. D A Lazzarino, M de Diego, E Musi, S Z Hirschman, R J Alexander. Immunol Lett. 2000;74(3):189-195. doi:10.1016/s0165-2478(00)00258-3.

Advanced Viral Research Corp (ADVR). ADVR reports AVR118 inhibits inflammatory arthritis in animal model and in rheumatoid arthritis patients in human clinical trial. ADVR press release, PR Newswire, December 3, 2003.